title: [Abnormality of blood coagulation indexes in patients with de novo acute leukemia and its clinical significance].
abstract: To explore hemorrhage risk and the clinical significance of abnormal change of prothrombin time (PT), activated partial thromboplastin time (APTT), plasma fibrinogen (FIB), plasma thrombin time (TT) and d-dimer (D-D) in de novo acute leukemia (except for APL), the different bleeding manifestations of 114 cases of de novo acute leukemia with different coagulation indexes were analyzed retrospectively. The correlation between these blood coagulation indexes and the possible correlative clinical characteristics were analysed, including age, sex, type of acute leukemia, initial white blood cell(WBC) and platelet(Plt) count, the proportion of blast cells in bone marrow and cytogenetic abnormality of patients at diagnosis. The results indicated that the incidence of abnormal blood coagulation was as high as 78.1% for de novo AL patients. These patients with 5 normal blood coagulation indexes may have mild bleeding manifestation, but the more abnormal indexes, the more severe bleeding. Both PT and D-D were sensitive indexes for diagnosis of level II bleeding. Incidence of abnormal blood coagulation significantly correlates with the proportion of blast cells in bone marrow (χ(2) = 4.184, OR = 1.021, P < 0.05) and more with D-D (P < 0.01), while age, sex, type of AL, WBC count, Plt count and abnormality of cytogenetics did not correlate with abnormal blood coagulation. It is concluded that the coagulation and fibrinolysis are abnormal in most patients with de novo acute leukemia. More abnormal indexes indicate more severe bleeding, and both PT and D-D are sensitive indexes for diagnosis of level II bleeding. Higher proportion of blast cells in bone marrow predicts higher incidence of abnormal blood clotting. Acute leukemia with elderly age, high white blood cell count and adverse cytogenetics do not predict severer abnormal blood clotting. Detection of PT, APTT, TT, FIB, and D-D may help to judge whether the patients are in a state of hypercoagulability or disseminated intravenous coagulation, which will provide experiment evidences for early intervention and medication.
authors.affiliation: Medical School of Chinese PLA, Beijing, China.
authors.forename: Fang-Fang
authors.initials: FF
authors.lastname: Xiao
authors.forename: Kai-Xun
authors.initials: KX
authors.lastname: Hu
authors.forename: Mei
authors.initials: M
authors.lastname: Guo
authors.forename: Jian-Hui
authors.initials: JH
authors.lastname: Qiao
authors.forename: Qi-Yun
authors.initials: QY
authors.lastname: Sun
authors.forename: Hui-Sheng
authors.initials: HS
authors.lastname: Ai
authors.forename: Chang-Lin
authors.initials: CL
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D002648:Child; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products; D006470:Hemorrhage / Q000473:pathology*; D006801:Humans; D007938:Leukemia / Q000097:blood* / Q000473:pathology*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011517:Prothrombin Time; D012189:Retrospective Studies; D013918:Thrombin Time; D055815:Young Adult
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D